10.28

1.08% +0.11

After Hours: 10.00 -0.28 -2.72%

Amicus Therapeutics Inc (FOLD)

Overview News Price History Option Chain Why FOLD Down? Discussions Forecast

Amicus Therapeutics Inc stock is currently priced at $10.28, with a 24-hour trading volume of 1.70M. It has seen a +1.08% increased in the last 24 hours and a -10.06% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $10.22 pivot point. If it approaches the $10.42 resistance level, significant changes may occur.

Previous Close:

$10.17

Open:

$10.26

24h Volume:

1.70M

Market Cap:

$3.04B

Revenue:

$399.36M

Net Income/Loss:

$-151.58M

P/E Ratio:

-16.06

EPS:

-0.64

Net Cash Flow:

$-76.53M

1W Performance:

-3.11%

1M Performance:

-10.06%

6M Performance:

-5.34%

1Y Performance:

-11.07%

1D Range:

$10.11

$10.32

52W Range:

$9.70

$14.57

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Name

Amicus Therapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

609-662-2000

Address

1 Cedar Brook Drive, Cranbury, NJ

Employee

325

Twitter

@amicusrx1

Next Earnings Date

2024-05-08

Latest SEC Filings

FOLD's Discussions on Twitter

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
Apr-13-22	Resumed	Goldman	Neutral
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-15-21	Upgrade	Stifel	Hold → Buy
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight
Jul-19-21	Resumed	BTIG Research	Buy
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-02-21	Initiated	Stifel	Hold
Feb-12-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-28-20	Resumed	Cantor Fitzgerald	Overweight
Dec-10-20	Downgrade	Citigroup	Buy → Neutral
Nov-11-20	Initiated	Berenberg	Hold
Jun-17-20	Initiated	BTIG Research	Buy
Feb-04-20	Resumed	Cantor Fitzgerald	Overweight
Nov-12-19	Reiterated	H.C. Wainwright	Buy
Jun-17-19	Initiated	H.C. Wainwright	Buy
Jun-05-19	Reiterated	Cantor Fitzgerald	Overweight
Apr-05-19	Initiated	Janney	Buy
Jan-30-19	Initiated	Cantor Fitzgerald	Overweight
Oct-29-18	Initiated	Citigroup	Neutral
Aug-17-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-06-17	Resumed	Goldman	Neutral
Sep-13-17	Reiterated	Chardan Capital Markets	Buy
Aug-10-17	Reiterated	Chardan Capital Markets	Buy
Jan-24-17	Upgrade	Robert W. Baird	Neutral → Outperform
May-18-16	Initiated	BofA/Merrill	Buy
Apr-14-16	Initiated	Robert W. Baird	Neutral
Apr-12-16	Reiterated	Chardan Capital Markets	Buy
Sep-16-15	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-16-15	Reiterated	Chardan Capital Markets	Buy

View All

Amicus Therapeutics Inc Stock (FOLD) Latest News

Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024

GlobeNewswire Inc.

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™

GlobeNewswire Inc.

Time to Buy These 3 Healthcare Companies That Raised Revenue Guidance?

Investing.com

Amicus Therapeutics Inc Stock (FOLD) Financials Data

Amicus Therapeutics Inc (FOLD) Revenue 2024

FOLD reported a revenue (TTM) of $399.36 million for the quarter ending December 31, 2023, a +21.30% rise year-over-year.

Amicus Therapeutics Inc (FOLD) Net Income 2024

FOLD net income (TTM) was -$151.58 million for the quarter ending December 31, 2023, a +35.92% increase year-over-year.

Amicus Therapeutics Inc (FOLD) Cash Flow 2024

FOLD recorded a free cash flow (TTM) of -$76.53 million for the quarter ending December 31, 2023, a +55.07% increase year-over-year.

Amicus Therapeutics Inc (FOLD) Earnings per Share 2024

FOLD earnings per share (TTM) was -$0.51 for the quarter ending December 31, 2023, a +37.80% growth year-over-year.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.